61 results
8-K
RYTM
Rhythm Pharmaceuticals Inc.
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
(the “Annual Report”). We have not yet completed our assessment of our internal control over financial reporting and the following material weakness … is subject to change upon completion of such assessment, which may also result in additional or different material weaknesses. Our independent registered
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
2 Nov 20
Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results
9:32am
with filings that initially receive accelerated assessment by the EMA, Rhythm's MAA recently has reverted from an accelerated assessment to a standard
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
6 Apr 22
Regulation FD Disclosure
8:01am
to VUS Functional Assessment “Low” “Mid” “High” Suspected Pathogenic Benign Likely Benign Likely pathogenic Pathogenic Uncertain Significance … of setmelanotide response Assessment of setmelanotide in patients with VUS variants to establish genotype - response correlations Collaboration
8-K
EX-99.1
kbw7soedmn1ln
3 Feb 21
Regulation FD Disclosure
12:00am
10-K
q174drdvlax836lam
12 Mar 18
Annual report
12:00am
424B4
vk0ix3n gaypi
21 Jun 18
Prospectus supplement with pricing info
4:55pm
DRS
8g6qpedmzwd
11 Jun 18
Draft registration statement
12:00am